solifenacin succinate suspension

DRUG3 trials

Sponsors

Astellas Pharma Inc, Astellas Pharma Europe B.V.

Conditions

Bioavailability of Solifenacin SuccinateHealthy VolunteersPharmacokinetics of Solifenacin SuccinateUrinary Bladder, Overactive

Phase 1

Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers

CompletedNCT01015040

Astellas Pharma IncBioavailability of Solifenacin Succinate, Healthy Volunteers, Pharmacokinetics of Solifenacin Succinate

Start: 2009-09-30End: 2009-11-30Updated: 2009-12-07

Phase 3

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

CompletedNCT01565707

Astellas Pharma Europe B.V.Urinary Bladder, Overactive

Start: 2012-06-07End: 2014-01-02Updated: 2024-10-31

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

CompletedNCT01655069

Astellas Pharma Europe B.V.Urinary Bladder, Overactive

Start: 2012-10-04End: 2014-10-08Updated: 2024-11-13

Related Papers

Relationship between mean volume voided and incontinence in children with overactive bladder treated with solifenacin: post hoc analysis of a phase 3 randomised clinical trial.

2020-04-01

Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial.

2016-09-2829 citations